CancerRadarCancerRadar
Updated daily

Cancer research, explained for everyone

CancerRadar scans newly published research and translates important findings into plain language.

Browse by cancer type

🎗️Breast Cancer
✦ Significant finding this week31 new findings this week
🩺Colorectal Cancer
✦ Significant finding this week9 new findings this week
🩸Leukemia
8 new findings this week
🫁Lung Cancer
✦ Significant finding this week32 new findings this week
☀️Melanoma
2 new findings this week
🎗️Ovarian Cancer
4 new findings this week
💜Pancreatic Cancer
2 new findings this week
🧬Prostate Cancer
4 new findings this week

Lifestyle & risk factors

How diet, weight, smoking, and environment relate to cancer risk, grounded in peer-reviewed research.

Browse topics →

Medical devices & procedures

Ablation, radiation therapy, robotic surgery: how these technologies work and what the evidence says.

Browse devices →

Research glossary

Immunotherapy, biomarkers, clinical trial phases: plain-language explanations of terms you'll see in research news.

Browse glossary →

Recent findings

View all →
Observational StudyPatterns observed in populations over time, not a controlled experiment.Breast CancerPublished: May 18, 2026

Obesity Linked to Poorer Outcomes in Young Women with Certain Breast Cancer

Researchers studied 5,094 premenopausal women with a specific type of breast cancer in China. They found that women who were obese had poorer outcomes compared to those who were underweight, normal weight, or overweight. The study suggests that obesity may be an independent risk factor for breast cancer recurrence in these women.

Why it matters: This finding may help doctors better understand how to treat young women with this type of breast cancer and how to manage their weight to improve their prognosis.
PubMed↗
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Lung CancerPublished: May 18, 2026

Combining Futibatinib and Binimetinib in Advanced Cancer Treatment

Researchers tested a combination of two cancer drugs, futibatinib and binimetinib, in lab experiments and a small clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation →. They found that the combination showed promise in treating certain types of lung cancer, but the trial was stopped due to side effects. The exact effectiveness of this combination is still unclear.

Why it matters: This study contributes to the ongoing search for effective treatments for advanced cancer, particularly for patients with KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation →-mutant non-small cell lung cancer.

The trial was stopped early due to side effects, and the sample size was small.

PubMed↗
ReviewSummary and analysis of existing published studies.Breast CancerPublished: May 18, 2026

Mapping Research on Preventing a Common Side Effect of Breast Cancer ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →

Researchers analyzed a large collection of studies on a type of medication called long-acting G-CSF, which helps prevent a serious side effect of breast cancer chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → called febrile neutropenia. They found that the research on this topic has grown rapidly and is now focusing on how to implement it in real-world practice. The study aimed to provide a clear overview of the current state of research on this topic.

Why it matters: This study may help identify future research priorities and provide a framework for navigating the complex evidence base on febrile neutropenia prevention.

The study analyzed a large collection of studies, but it did not present any new data or results.

PubMed↗
ReviewSummary and analysis of existing published studies.Breast CancerPublished: May 18, 2026

Genomic Science and Breast Cancer in Males

Researchers looked at how genomic science can help identify and treat breast cancer in males. They found that individuals with a family history of breast cancer may be at higher risk. This is an area where nurses can play a key role in providing care.

Why it matters: This research highlights the importance of genomic science in understanding and treating breast cancer in males, particularly in those with a family history.
PubMed↗
Observational StudyPatterns observed in populations over time, not a controlled experiment.Breast CancerPublished: May 18, 2026

Kenyan Study Tests New Approach to Increase Breast and Cervical Cancer Screenings

Researchers in Kenya are testing a new program called C3Link to see if it can increase the number of women getting breast and cervical cancer screenings. The program includes community and clinic strategies to address barriers to screening. The study will compare the C3Link program to usual care.

Why it matters: This study could provide insights into how to improve cancer screening rates in low-resource settings.
PubMed↗
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Phase 3 TrialLarge controlled trial comparing treatments. The strongest level of trial evidence.Lung CancerPublished: May 18, 2026

New Insights into Lung Cancer Treatment without Tobacco History

Researchers analyzed data from 741 patients with lung cancer who never smoked and didn't have specific genetic mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →. They found that high levels of certain proteins and immune cells in the tumor were associated with better treatment outcomes. The study suggests that combining different treatments may improve results for these patients.

Why it matters: This finding could help doctors choose the best treatment options for patients with lung cancer who don't smoke and don't have specific genetic mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →.
Efficacy

Objective response rate was 23.2%, median progression-free survival was 4.5 months, and median overall survival was 16.8 months.

PubMed↗

What is CancerRadar?

CancerRadar is a public research monitor. It scans peer-reviewed publications, clinical trial registries, and authoritative sources daily, then explains what is new and why it might matter, without overstating the evidence.

Every finding is linked to its original source. Evidence stages are labeled clearly: preclinical, trial phase, observational, or review-level. We do not diagnose, recommend treatment, or give medical advice.

Read our methodology →